N/A N=20 Fractionated Stereotactic Radiosurgery for Large Brain Metastases
Large Brain Mets
Primary: Number of Patients Experiencing DLT — 0; 0; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
Metastatic Malignant Neoplasm to Brain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Tolerated Dose (MTD) of Hypofractionated Radiosurgery Defined as the Highest Dose Level Where a Grade 3 or Greater With an Attribution Score of ≥ 3 Develops in ≤…
N/A N=13 A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases
Brain Metastases
Primary: Maximum Tolerated Dose of Five Fraction Stereotactic Radiotherapy — 35; 30 Gy
N/A N=56 Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
Brain Cancer · Neoplasm Metastasis · Cancer of Brain and Nervous System
Primary: Stereotactic Radiosurgery (SRS) Maximum-tolerated Dose (MTD) — 0; 0; 0; 0 Dose-limited toxicity (DLT) events
N/A N=3 Stereotactic Body Radiation Therapy (SBRT) for Liver Mets
Liver Metastases
Primary: Maximum Tolerated Dose (MTD) — 60 Gy
N/A N=30 Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction
Metastatic Carcinoma
Primary: Number of Participants With SABR Successfully Delivered in One Fraction — 30 Participants
N/A N=38 Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors
Lung Cancer
Primary: Disease Status — 84; 78; 55; 54 percentage of participants
N/A N=40 Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients
Phase 2 N=68 Hypofractionated Stereotactic Body Radiation Therapy (SBRT)
Prostate Cancer
Primary: Percentage of Patients With a Minimally Detected Decline (MDD) in Quality of Life (QOL) — 17; 18; 41; 19 percentage of patients
Phase 3 N=16 Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases
Spinal Metastases
Primary: Local Tumor Control Using MRI or CT
Phase 2 N=59 Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: To Determine the Rate of (Grade 2 or Greater) Gastrointestinal Toxicity Attributable to Gemcitabine and Fractionated SBRT at One Year. — 5 Number of toxicities.
Phase 3 N=83 Comparing Two Forms of Head Immobilization for Stereotactic Radiotherapy
Patients Receiving Fractionated Stereotactic Radiotherapy · for Brain Tumors
Primary: Distance From Ideal to Center of GTC Frame and BrainLab Thermoplastic Mask With Respect to Average and Variability — 2.00; 3.17 millimeters
N/A N=21 Stereotactic Body Radiation Therapy (SBRT) for Tumors Near the Spinal Cord
Spinal Tumors
Primary: Toxicity — 14; 0; 0; 0 participants
N/A N=10 One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors
Lung Cancer · Oligometastatic Lung Tumor
Primary: Feasibility of the ONE STOP Workflow as Measured by the Number of Participants With Successful Completion of the ONE STOP Workflow Through Treatment Delivery — 8…
N/A N=18 Protocol for Staged Stereotactic Radiosurgery for Large Arteriovenous Malformations
Intracranial Arteriovenous Malformations (AVM)
Primary: Number of Participants With Presence of T2 Weighted Changes on Serial MRI Exam Associated With New Neurological Symptoms — 2 participants
Phase 1 N=17 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Ependymoma · Adult Anaplastic Oligodendroglioma
Primary: Maximum Tolerated Dose (MTD) of Alisertib — 50 mg dose of Alisertib
N/A N=30 MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer
Prostate Cancer
Primary: Feasibility of Delivering Stereotactic Body Radiotherapy(SBRT) With Simultaneous Integrated Boost(SIB). — 9; 14; 2; 5 Participants
Phase 2 N=10 Locally Advanced NSCLC Hyperfractionated RT
Carcinoma, Non Small Cell Lung (NSCLC)
Primary: The Metabolic Complete Response Rate, Assessed Using Interim PET-CT, in an Accelerated Fashion (2 Gy/Fraction, 6 Fractions/Week) With Concurrent Chemotherapy — 1; 6; 1…
Phase 3 N=103 Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Overall Survival of Standard Radiation (CFRT) Versus Accelerated, Hypofractionated, Image-guided Conformal Radiotherapy (IGRT) in Treatment of Stage II-III NSCLC in…
N/A N=92 Individualized Stereotactic Body Radiotherapy of Liver Metastases
Solid Tumor · Liver Metastases
Primary: Local Control Rate — 77 percentage of participants
N/A N=7 Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer
Liver Cancer
Primary: The Safety of Hypofractionated Stereotactic Radiotherapy in Patients With Advanced Hepatocellular Carcinoma — 0; 0; 1; 3 Participants
Phase 2 N=51 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Brain Metastasis · Bladder Cancer · Breast Cancer
Primary: Local Control — 13; 23; 2; 1 participants
Phase 3 N=213 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Breast Cancer · Cognitive/Functional Effects · Lung Cancer
Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001
N/A N=40 SIMT Stereotactic Radiosurgery Outcomes Study
Brain Metastases, Adult
Primary: Number of Participants Who Live Longer Than Predicted According to the Graded Prognostic Assessment (GPA) Score — 22 Participants
N/A N=22 Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
N/A N=55 Phase I Study of Accelerated Hypofractionated Image-Guided Radiation Therapy
Non-small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicity — 1; 1; 1 Participants
Phase 2 N=71 Evaluation of Single Session Stereotactic Body Radiotherapy
Spinal Neoplasms
Primary: Complete Pain Relief Using Stereotactic Body Radiotherapy (SBRT) to Treat Spine and Para- Spinal Tumors in a Single Session — 18 Participants
Phase 3 N=194 Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
Cognitive/Functional Effects · Metastatic Cancer · Neurotoxicity
Primary: Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT — 3.0; 3.7 Months — p=<0.0001
N/A N=41 A Proof-of-principle Study of HBO-SRS for Brain Metastases
Brain Metastases
Primary: The Average Time From HBO Chamber Exit to SRS beam-on — 8.3 minutes
N/A N=35 Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer
Lung Cancer
Primary: Boost Dose Toxicity — 5 Participants